- Home
- SPXC vs LCTX Comparison
SPXC vs LCTX Comparison
Compare SPXC & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPXC
- LCTX
- Stock Information
- Founded
- SPXC 1912
- LCTX 1990
- Country
- SPXC United States
- LCTX United States
- Employees
- SPXC N/A
- LCTX N/A
- Industry
- SPXC Industrial Machinery/Components
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SPXC Industrials
- LCTX Health Care
- Exchange
- SPXC Nasdaq
- LCTX Nasdaq
- Market Cap
- SPXC N/A
- LCTX 95.2M
- IPO Year
- SPXC N/A
- LCTX N/A
- Fundamental
- Price
- SPXC $148.90
- LCTX $0.45
- Analyst Decision
- SPXC Hold
- LCTX Strong Buy
- Analyst Count
- SPXC 3
- LCTX 5
- Target Price
- SPXC $179.50
- LCTX $4.20
- AVG Volume (30 Days)
- SPXC 250.4K
- LCTX 904.3K
- Earning Date
- SPXC 05-01-2025
- LCTX 05-13-2025
- Dividend Yield
- SPXC N/A
- LCTX N/A
- EPS Growth
- SPXC 109.74
- LCTX N/A
- EPS
- SPXC 4.31
- LCTX N/A
- Revenue
- SPXC $2,001,300,000.00
- LCTX $9,499,000.00
- Revenue This Year
- SPXC $11.20
- LCTX N/A
- Revenue Next Year
- SPXC $5.85
- LCTX $232.66
- P/E Ratio
- SPXC $34.42
- LCTX N/A
- Revenue Growth
- SPXC 10.78
- LCTX 6.19
- 52 Week Low
- SPXC $115.00
- LCTX $0.37
- 52 Week High
- SPXC $183.83
- LCTX $1.40
- Technical
- Relative Strength Index (RSI)
- SPXC 66.98
- LCTX 47.88
- Support Level
- SPXC $130.01
- LCTX $0.37
- Resistance Level
- SPXC $153.12
- LCTX $0.48
- Average True Range (ATR)
- SPXC 4.08
- LCTX 0.04
- MACD
- SPXC 2.16
- LCTX 0.00
- Stochastic Oscillator
- SPXC 85.30
- LCTX 49.73
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.